C-X-Cケモカイン受容体4（CXCR4）拮抗薬の世界市場レポート 2025年

C-X-Cケモカイン受容体4（CXCR4）拮抗薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.3％で25億4,000万米ドルに成長します。予測期間における成長は、HIVやAIDSにおける用途の拡大、幹細胞動員に対する需要の高まり、自己免疫疾患における可能性、バイオバンク構想の成長、創薬における人工知能（AI）の統合などに起因すると考えられます。予測期間における主な動向としては、希少疾病用医薬品開発への注目の高まり、併用療法の開発、精密腫瘍学的アプローチの採用、新規療法の臨床試験の拡大、ドラッグデリバリー技術の進歩などが挙げられます。

ヒト免疫不全ウイルス（HIV）有病率の上昇は、痙攣性発声障害治療市場の成長を促進すると予想されます。HIVは、CD4（T）細胞を攻撃することで免疫系を標的とし弱体化させるウイルスであり、治療しなければAIDSにつながる可能性があります。HIVの有病率が増加しているのは、認知度の低さ、医療アクセスの制限、トランスミッション率の高さ、地域によっては予防が不十分であるなどの要因によるものです。CXCR4アンタゴニストは、CXCR4レセプターを阻害することによりHIVを管理し、ウイルスが免疫細胞にアクセスし感染するのを防ぐ。例えば、国連合同エイズ計画（UNAIDS）によると、2022年には世界で3,900万人［3,310万～4,570万人］のHIV感染者がおり、その年の新規感染者は130万人［100万～170万人］でした。その結果、HIVの有病率の増加がCXCR4拮抗薬市場の拡大に拍車をかけています。

CXCR4拮抗薬市場の主要企業は、様々な疾患の治療選択肢と患者の転帰を改善するため、生物学的同等物の開発に注力しています。生物学的同等製剤とは、同様の条件下で比較した場合に同様の生物学的利用能を有する医薬品のことです。例えば、2024年5月、インドのジェネリック注射剤メーカーであるGland Pharma社は、米国食品医薬品局（FDA）からプレリキサフォー注射剤の承認を取得しました。この製品は、ジェンザイム・コーポレーションの基準薬であるMOZOBIL（プレリキサホル）注射剤と生物学的に同等であり、治療上も同等です。プレリキサホールはCXCR4拮抗薬であり、非ホジキンリンパ腫および多発性骨髄腫患者において造血幹細胞を末梢血に動員し、採取および自家移植するために顆粒球コロニー刺激因子と併用されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界C-X-Cケモカイン受容体4（CXCR4）拮抗薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：成長率分析
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場の実績：規模と成長, 2019-2024
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界C-X-Cケモカイン受容体4（CXCR4）拮抗薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• BL-8040
• GMI-1359
• プレリキサフォール（AMD3100）
• バリキサフォルチド（POL6326）
• USL311
• ブリキサフォール（GPC-100）
• その他のタイプ
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場製品パイプライン別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 承認
• 臨床試験
• 前臨床
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• ヒト免疫不全ウイルス（HIV）
• 慢性炎症疾患
• 幹細胞動員
• 免疫疾患と自己免疫疾患
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場BL-8040のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学への応用（白血病、リンパ腫）
• 幹細胞動員
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場GMI-1359のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん治療（乳がん、固形腫瘍）
• 骨髄移植
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場プレリキサフォール（AMD3100）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 造血幹細胞動員
• がん治療（多発性骨髄腫）
• HIV治療（HIVリザーバー）
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場バリキサフォルチド（POL6326）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん治療（固形腫瘍、乳がん）
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場USL311のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 幹細胞動員
• 腫瘍学アプリケーション
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場、ブリキサフォール（GPC-100）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん治療（リンパ腫、固形腫瘍）
• 幹細胞動員
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 実験的または前臨床的CXCR4拮抗薬
• CXCR4拮抗薬との併用療法

第7章 地域別・国別分析

• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のC-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• C-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：競合情勢
• C-X-Cケモカイン受容体4（CXCR4）拮抗薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline
• Eli Lilly and Company
• Amgen Inc.
• Takeda Chemical Industries Ltd.
• Kyowa Kirin Co. Ltd.
• BioLegend Inc.
• Kura Oncology Inc.
• CUSABIO TECHNOLOGY LLC
• Cayman Chemical
• X4 Pharmaceuticals Inc.
• BioLineRx Ltd.
• Spexis Ltd.
• Biokine Therapeutics Ltd.
• GlycoMimetics
• AnorMED Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• C-X-Cケモカイン受容体4（CXCR4）拮抗薬市場2029：新たな機会を提供する国
• C-X-Cケモカイン受容体4（CXCR4）拮抗薬市場2029：新たな機会を提供するセグメント
• C-X-Cケモカイン受容体4（CXCR4）拮抗薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

C-X-C chemokine receptor 4 (CXCR4) antagonists are pharmaceutical compounds aimed at inhibiting the CXCR4 receptor, which is found on the surface of specific cells. These antagonists function by blocking the interaction between CXCR4 and its ligand, CXCL12 (also known as SDF-1), a key player in cell migration, hematopoiesis, and immune responses.

The main types of CXCR4 antagonists include BL-8040, GMI-1359, plerixafor (AMD3100), balixafortide (POL6326), USL311, burixafor (GPC-100), and others. These antagonists can be administered orally or via injection. BL-8040, for example, is a synthetic peptide developed to block CXCR4, which is involved in cancer cell migration and survival. The product pipelines feature both approved clinical trials and pre-clinical trials for a range of applications, including cancer, human immunodeficiency virus (HIV), chronic inflammatory diseases, stem cell mobilization, and immune and autoimmune diseases. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The C-X-C chemokine receptor 4 (CXCR4) antagonist market research report is one of a series of new reports from The Business Research Company that provides C-X-C chemokine receptor 4 (CXCR4) antagonist market statistics, including C-X-C chemokine receptor 4 (CXCR4) antagonist industry global market size, regional shares, competitors with a C-X-C chemokine receptor 4 (CXCR4) antagonist market share, detailed C-X-C chemokine receptor 4 (CXCR4) antagonist market segments, market trends and opportunities, and any further data you may need to thrive in the C-X-C chemokine receptor 4 (CXCR4) antagonist industry. This C-X-C chemokine receptor 4 (CXCR4) antagonist market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The C-X-C chemokine receptor 4 (CXCR4) antagonists market size has grown strongly in recent years. It will grow from $1.62 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing transparency in clinical trial data, patient-centric healthcare policies, rising prevalence of chemotherapy resistance, policies emphasizing patient-centered care and access, and increasing preference for targeted therapies.

The C-X-C chemokine receptor 4 (CXCR4) antagonists market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to expanding applications in HIV or AIDS, rising demand for stem cell mobilization, potential in autoimmune diseases, growth in biobanking initiatives, and integration of artificial intelligence (AI) in drug discovery. Major trends in the forecast period include increasing focus on orphan drug development, development of combination therapies, adoption of precision oncology approaches, expanding clinical trials for novel therapies, and advancements in drug delivery technologies.

The rise in human immunodeficiency virus (HIV) prevalence is expected to drive growth in the spasmodic dysphonia treatment market. HIV, a virus that targets and weakens the immune system by attacking CD4 (T) cells, can lead to AIDS if untreated. The increasing prevalence of HIV is due to factors such as low awareness, limited healthcare access, high transmission rates, and inadequate prevention in some regions. CXCR4 antagonists help manage HIV by blocking the CXCR4 receptor, preventing the virus from accessing and infecting immune cells, thus aiding in controlling the virus and enhancing immune response. For instance, according to Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, there were 39 million [33.1 million-45.7 million] people living with HIV globally, with 1.3 million [1 million-1.7 million] new infections that year. Consequently, the growing prevalence of HIV is fueling the expansion of the CXCR4 antagonist market.

Leading companies in the CXCR4 antagonist market are focusing on developing bioequivalents to improve treatment options and patient outcomes for various diseases. Bioequivalents are pharmaceutical products that have similar bioavailability when compared under similar conditions. For example, in May 2024, Gland Pharma, an India-based generic injectable manufacturer, received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection. This product is bioequivalent and therapeutically equivalent to the reference drug, MOZOBIL (plerixafor) injection by Genzyme Corporation. Plerixafor is a CXCR4 antagonist used in conjunction with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

In April 2024, PANTHERx, a US-based specialty pharmacy, partnered with X4 Pharmaceuticals Inc. to facilitate the distribution of XOLREMDI (mavorixafor). This oral treatment, taken once daily, selectively antagonizes the CXCR4 receptor and was approved by the U.S. Food and Drug Administration (FDA). It is the first FDA-approved therapy specifically indicated for patients aged 12 and older with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. X4 Pharmaceuticals Inc., a US-based late-stage clinical biopharmaceutical company, focuses on developing and commercializing novel therapeutics, including CXCR4 antagonists such as XOLREMDI (mavorixafor).

Major companies operating in the C-X-C chemokine receptor 4 (CXCR4) antagonists market are Pfizer Inc., F-Hoffmann La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Takeda Chemical Industries Ltd., Kyowa Kirin Co. Ltd., BioLegend Inc., Kura Oncology Inc., CUSABIO TECHNOLOGY LLC, Cayman Chemical, X4 Pharmaceuticals Inc., BioLineRx Ltd., Spexis Ltd., Biokine Therapeutics Ltd., GlycoMimetics, AnorMED Inc., CohBar Inc.

North America was the largest region in the C-X-C chemokine receptor type 4 antagonists market in 2024. The regions covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The C-X-C chemokine receptor 4 (CXCR4) antagonist market consists of sales of TN14003 (Trogarzo), X4P-001 (Mavorixafor), TG-0054, and KRH-3955. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on c-x-c chemokine receptor 4 (cxcr4) antagonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for c-x-c chemokine receptor 4 (cxcr4) antagonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The c-x-c chemokine receptor 4 (cxcr4) antagonists market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: BL-8040; GMI-1359; Plerixafor (AMD3100); Balixafortide (POL6326); USL311; Burixafor (GPC-100); Other Types
• 2) By Route Of Administration: Oral; Injectable
• 3) By Product Pipeline: Approved; Clinical Trials; Pre-Clinical
• 4) By Application: Cancer; Human Immunodeficiency Virus (HIV); Chronic Inflammatory Disease; Stem Cell Mobilization; Immune And Autoimmune Diseases
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By BL-8040: Oncology Applications (Leukemia, Lymphoma); Stem Cell Mobilization
• 2) By GMI-1359: Cancer Treatment (Breast Cancer, Solid Tumors); Bone Marrow Mobilization
• 3) By Plerixafor (AMD3100): Hematopoietic Stem Cell Mobilization; Cancer Treatment (Multiple Myeloma); HIV Treatment (HIV Reservoirs)
• 4) By Balixafortide (POL6326): Cancer Treatment (Solid Tumors, Breast Cancer)
• 5) By USL311: Stem Cell Mobilization; Oncology Applications
• 6) By Burixafor (GPC-100): Cancer Treatment (Lymphoma, Solid Tumors); Stem Cell Mobilization
• 7) By Other Types: Experimental Or Preclinical CXCR4 Antagonists; Combination Therapies With CXCR4 Antagonists
• Companies Mentioned: Pfizer Inc.; F-Hoffmann La Roche Ltd.; Sanofi; Bristol-Myers Squibb Company; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Characteristics

3. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Trends And Strategies

4. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Growth Analysis And Strategic Analysis Framework

• 5.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Growth Rate Analysis
• 5.4. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Total Addressable Market (TAM)

6. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Segmentation

• 6.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BL-8040
• GMI-1359
• Plerixafor (AMD3100)
• Balixafortide (POL6326)
• USL311
• Burixafor (GPC-100)
• Other Types
• 6.2. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Approved
• Clinical Trials
• Pre-Clinical
• 6.4. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Human Immunodeficiency Virus (HIV)
• Chronic Inflammatory Disease
• Stem Cell Mobilization
• Immune And Autoimmune Diseases
• 6.5. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of BL-8040, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology Applications (Leukemia, Lymphoma)
• Stem Cell Mobilization
• 6.7. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of GMI-1359, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Treatment (Breast Cancer, Solid Tumors)
• Bone Marrow Mobilization
• 6.8. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Plerixafor (AMD3100), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cell Mobilization
• Cancer Treatment (Multiple Myeloma)
• HIV Treatment (HIV Reservoirs)
• 6.9. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Balixafortide (POL6326), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Treatment (Solid Tumors, Breast Cancer)
• 6.10. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of USL311, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stem Cell Mobilization
• Oncology Applications
• 6.11. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Burixafor (GPC-100), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Treatment (Lymphoma, Solid Tumors)
• Stem Cell Mobilization
• 6.12. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Experimental Or Preclinical CXCR4 Antagonists
• Combination Therapies With CXCR4 Antagonists

7. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Regional And Country Analysis

• 7.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 8.1. Asia-Pacific C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 9.1. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 9.2. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 10.1. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 11.1. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 11.2. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 12.1. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 13.1. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 14.1. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 14.2. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 15.1. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 15.2. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 16.1. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 17.1. Germany C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 18.1. France C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 19.1. Italy C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 20.1. Spain C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 21.1. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 21.2. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 22.1. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 23.1. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 23.2. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 24.1. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 24.2. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 25.1. Canada C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 25.2. Canada C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 26.1. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 26.2. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 27.1. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 28.1. Middle East C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 28.2. Middle East C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

• 29.1. Africa C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
• 29.2. Africa C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Competitive Landscape And Company Profiles

• 30.1. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Competitive Landscape
• 30.2. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Takeda Chemical Industries Ltd.
• 31.5. Kyowa Kirin Co. Ltd.
• 31.6. BioLegend Inc.
• 31.7. Kura Oncology Inc.
• 31.8. CUSABIO TECHNOLOGY LLC
• 31.9. Cayman Chemical
• 31.10. X4 Pharmaceuticals Inc.
• 31.11. BioLineRx Ltd.
• 31.12. Spexis Ltd.
• 31.13. Biokine Therapeutics Ltd.
• 31.14. GlycoMimetics
• 31.15. AnorMED Inc.

32. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

34. Recent Developments In The C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

35. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market High Potential Countries, Segments and Strategies

• 35.1 C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market In 2029 - Countries Offering Most New Opportunities
• 35.2 C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market In 2029 - Segments Offering Most New Opportunities
• 35.3 C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer